Privia Health
PRVA
20.30
+0.02
+0.10%
Privia Health
US · PRVA
#2604 by market cap
Listed 2021
20.30
+0.02
+0.10%
Live - 5344 symbols - heartbeat 68s ago
· 2026-10-07 19:54
After-hours
20.30
0.00%
- Market cap
- 2.59B
- P/E (TTM)i
- 92.27
- P/Bi
- 3.31
- EPSi
- 0.18
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on PRVA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.46, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +22.26% YoY
Margins
- Gross margin
- 9.87%
- Operating margin
- 1.61%
- Net margin
- 1.08%
Key ratios & quality
- Altman Z-Scorei
- 4.46
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 657.61M | 786.36M | 817.08M | 966.22M | 1.36B | 1.66B | 1.74B | 2.12B |
| Gross profit | 56.46M | 68.47M | 82.58M | 63.66M | 134.78M | 161.50M | 176.85M | 209.43M |
| Selling & admin expenses | 53.23M | 50.98M | 55.36M | 278.63M | 149.33M | 134.32M | 152.60M | 165.29M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 2.16M | 16.06M | 25.38M | -217.44M | -19.12M | 20.65M | 16.98M | 34.24M |
| Pretax profit | -4.27M | 9.15M | 23.46M | -218.51M | -18.58M | 29.02M | 27.87M | 43.94M |
| Tax | -76.00K | 1.21M | -7.44M | -27.86M | -6.52M | 7.99M | 10.83M | 14.21M |
| Net profit | -4.19M | 7.95M | 30.90M | -190.65M | -12.06M | 21.03M | 17.04M | 29.73M |
| Basic EPS | 0 | 0 | 0 | -2 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.03 | 0.08 | 0.30 | -1.83 | -0.08 | 0.19 | 0.11 | 0.18 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 480.10M | 521.15M | 580.42M | 541.17M | 603.85M | 632.63M |
| Gross profit | 45.76M | 50.24M | 63.77M | 49.66M | 60.31M | 62.79M |
| Selling & admin expenses | 38.64M | 44.32M | 46.60M | 35.72M | 49.61M | 47.66M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 5.22M | 3.34M | 14.40M | 11.28M | 7.42M | 11.77M |
| Pretax profit | 8.15M | 5.74M | 16.67M | 13.37M | 9.31M | 16.75M |
| Tax | 2.10M | 2.46M | 6.87M | 2.79M | 5.60M | 7.02M |
| Net profit | 6.05M | 3.29M | 9.81M | 10.59M | 3.71M | 9.73M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.03 | 0.02 | 0.05 | 0.07 | 0.02 | 0.07 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | -- | 129.60M | 190.08M | 446.68M | 551.96M | 700.80M | 834.82M | 911.00M |
| Cash & ST investments | -- | 46.89M | 84.63M | 320.58M | 347.99M | 389.51M | 491.15M | 479.69M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | -- | 270.21M | 328.97M | 686.37M | 792.81M | 999.90M | 1.14B | 1.37B |
| Total current liabilities | -- | 115.22M | 146.94M | 190.46M | 264.27M | 386.95M | 449.15M | 568.52M |
| Short-term debt | -- | 3.38M | 875.00K | 3.77M | 3.01M | 3.04M | 2.55M | 2.20M |
| Long-term debt | -- | 39.73M | 32.78M | 31.69M | -- | -- | -- | -- |
| Total liabilities | -- | 162,749,000.00 | 185,317,000.00 | 236,192,000.00 | 273,764,000.00 | 392,511,000.00 | 452,336,000.00 | 578,435,000.00 |
| Total equity | -- | 107.46M | 143.65M | 450.18M | 519.05M | 607.39M | 683.45M | 790.94M |
| Retained earnings | -- | -51.12M | -19.88M | -208.11M | -216.69M | -193.61M | -179.23M | -156.31M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 886.47M | 882.96M | 970.93M | 911.00M | 966.02M | 1.03B |
| Cash & ST investments | 469.33M | 390.13M | 441.35M | 479.69M | 419.52M | 412.20M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.18B | 1.27B | 1.35B | 1.37B | 1.42B | 1.49B |
| Total current liabilities | 470.81M | 534.85M | 582.91M | 568.52M | 601.30M | 634.44M |
| Short-term debt | 2.39M | 2.50M | 2.56M | 2.20M | 2.11M | 2.07M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 474,012,000.00 | 538,996,000.00 | 588,226,000.00 | 578,435,000.00 | 611,988,000.00 | 650,508,000.00 |
| Total equity | 709.53M | 733.55M | 762.76M | 790.94M | 805.90M | 838.07M |
| Retained earnings | -175.01M | -172.32M | -165.46M | -156.31M | -153.25M | -144.20M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 5.25M | 24.36M | 38.89M | 55.06M | 47.20M | 80.79M | 109.28M | 163.40M |
| Depreciation & amortization | 1.07M | 1.43M | 1.83M | 2.46M | 4.57M | 6.53M | 7.27M | 9.91M |
| Free cash flow | 5.03M | 18.65M | 38.51M | 54.51M | 47.20M | 80.79M | 109.28M | 163.40M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 0 | 223.69M | -- | -- | -- | -- |
| Ending cash balance | 39.11M | 46.89M | 84.63M | 320.58M | 347.99M | 389.51M | 491.15M | 479.69M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -24.06M | 7.97M | 51.99M | 127.50M | -49.47M | 1.10M |
| Depreciation & amortization | 1.90M | 2.58M | 2.77M | 2.66M | 3.28M | 3.36M |
| Free cash flow | -24.06M | 7.97M | 51.99M | 127.50M | -49.47M | 1.10M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 469.33M | 390.13M | 441.35M | 479.69M | 419.52M | 412.20M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | 7.48 | 24.32 | -65.63 | -1.85 | 4.35 | 2.40 | 3.34 |
| ROA %i | -- | 3.05 | 10.43 | -37.08 | -1.16 | 2.57 | 1.35 | 1.83 |
| ROIC %i | -- | 9.29 | 19.56 | -57.30 | -1.75 | 4.27 | 2.38 | 3.30 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -6.27 | -7.28 | -11.48 |
| EBIT margin %i | 0.33 | 2.04 | 3.11 | -22.50 | -1.41 | 1.25 | 0.98 | 1.61 |
| FCF / sales %i | 0.76 | 2.37 | 4.71 | 5.64 | 3.47 | 4.87 | 6.29 | 7.70 |
| Current ratioi | -- | 1.12 | 1.29 | 2.35 | 2.09 | 1.81 | 1.86 | 1.60 |
| Quick ratioi | -- | 1.08 | 1.25 | 2.30 | 2.03 | 1.76 | 1.80 | 1.55 |
| Debt / assetsi | -- | 15.95 | 10.23 | 6.77 | 1.45 | 0.83 | 0.49 | 0.70 |
| LT debt / equityi | -- | 36.04 | 22.34 | 10.01 | 1.70 | 0.93 | 0.48 | 0.99 |
| Interest coveragei | 0.34 | 2.32 | 13.24 | -203.21 | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 13.68 | 19.94 | 26.60 | 21.58 | 16.10 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -9.60 | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | 121.31 | 36.28 | 28.01 | 26.09 | 51.28 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 2.53 | 2.32 | 2.74 | 3.34 | 3.08 | 3.84 |
| ROA %i | 1.41 | 1.26 | 1.46 | 1.83 | 1.67 | 2.04 |
| ROIC %i | 2.50 | 2.30 | 2.72 | 3.30 | 3.05 | 3.80 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 1.19 | 1.03 | 1.38 | 1.61 | 1.62 | 1.90 |
| FCF / sales %i | 6.57 | 4.83 | 5.42 | 7.70 | 6.14 | 5.56 |
| Current ratioi | 1.88 | 1.65 | 1.67 | 1.60 | 1.61 | 1.62 |
| Quick ratioi | 1.82 | 1.56 | 1.61 | 1.55 | 1.55 | 1.55 |
| Debt / assetsi | 0.46 | 0.52 | 0.46 | 0.70 | 0.64 | 0.59 |
| LT debt / equityi | 0.46 | 0.61 | 0.52 | 0.99 | 0.92 | 0.85 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Care for its patients’ needs100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.